Chemistry:Revefenacin
From HandWiki
Revefenacin, sold under the brand name Yupelri, is a medication for the treatment of chronic obstructive pulmonary disease (COPD). It was approved for use in the United States in 2018.[1] It was developed by Theravance Biopharma and is marketed by Mylan. Revefenacin is formulated as a solution that is nebulized and inhaled.[2]
Revefenacin is a bronchodilator that exerts its effect as a long-acting muscarinic antagonist.[3]
Society and culture
Brand names
In some countries, Yupelri is marketed by Viatris after Upjohn merged with Mylan to create Viatris.[4][5]
References
- ↑ "Theravance Biopharma and Mylan Receive FDA Approval for Yupelri (revefenacin) in Adults with Chronic Obstructive Pulmonary Disease" (Press release). Mylan. 9 November 2018. Archived from the original on 15 September 2019. Retrieved 17 January 2019.
- ↑ "Revefenacin: First Global Approval". Drugs 79 (1): 85–91. January 2019. doi:10.1007/s40265-018-1036-x. PMID 30560478.
- ↑ "Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis". BMC Pulmonary Medicine 20 (1). May 2020. doi:10.1186/s12890-020-1156-4. PMID 32393215.
- ↑ "Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan". Pfizer. 16 November 2020. https://www.businesswire.com/news/home/20201116005378/en/.
- ↑ "Brands". 16 November 2020. https://www.viatris.com/en/products/brands.
 |  |
